Acadia Pharmaceuticals (ACAD) Interest Expenses (2011 - 2026)

Acadia Pharmaceuticals' Interest Expenses history runs 16 years deep, the most recent figure standing at $5.9 million for Q1 2026.

• On a quarterly basis, Interest Expenses fell 90.75% year-over-year to $5.9 million in Q1 2026; TTM through Mar 2026 was $5.9 million, a 90.75% decrease from a year earlier, with the FY2025 full-year figure at $79.3 million, up 275.21% from the prior year.
• Interest Expenses improved to $5.9 million in Q1 2026 per ACAD's latest filing, from $3.2 million in the prior quarter.
• Across five years, Interest Expenses topped out at $71.4 million in Q1 2023 and bottomed at $2.4 million in Q4 2022.
• The 5-year median for Interest Expenses is $9.9 million (2024), against an average of $21.7 million.
• Across the five-year window, Interest Expenses jumped 689.51% in 2023 and sank 90.75% in 2026, its largest moves.
• Year by year, Interest Expenses stood at $2.4 million in 2022, then climbed by 1.4% to $2.4 million in 2023, then advanced by 7.52% to $2.6 million in 2024, then rose by 24.05% to $3.2 million in 2025, then soared by 85.22% to $5.9 million in 2026.
• Per Business Quant, the three latest ACAD Interest Expenses figures stand at $5.9 million (Q1 2026), $3.2 million (Q4 2025), and $11.4 million (Q3 2025).